艾艾

ONE 我至今都会记得我与艾艾相识的情景。枯芜灼烧的夏日，浮躁的阳光以及轻佻的风，我坐在两棵杨树的中间，眯起眼睛做复习。然后一个穿白色上衣，眼睛灼亮的女孩跑过来说，你挡住了我的太阳。

Establishment of AIDS Animal Model with SIVmac239 Infected Chinese Rhesus Monkey

In the present research,two Chinese rhesus monkeys were inoculated intravenously with 5000 TCID50 of SIVmac239. The changes in the numbers of CD4+ T lymphocyte in peripheral blood,plasma viral loads,proviral DNA and humoral antibodies against virus were periodically monitored during 121 days. At the early stage of infection,proviral DNA had been detected in PBMCs,and infectious SIVmac239 virus had been isolated from PBMCs. At the same period,the numbers of CD4+ T lymphocytes were significantly decreased,and maintained at low level during the 121-day period of infection. Plasma viral loads reached the peak at week 2 post-inoculation and kept at a steady state subsequently. Moreover,antibodies against viral proteins were detected from plasma. All the results showed that the two Chinese rhesus monkeys had been infected with SIVmac239 successfully. This animal model can be applied for further AIDS researches.

A General Introduction of HIV/AIDS Treatment with Traditional Chinese Medicine in China

This paper gives a general introduction of HIV/AIDS treatment with Traditional Chinese Medicine (TCM) in China during the past 20 years. Although the role of TCM in treatment of HIV/AIDS is promising,there is still a long way to go.

Development and Challenge of HIV/AIDS Testing Laboratory Network and Quality Assurance System in China

This paper describes the development and challenge of HIV/AIDS testing laboratory network and quality assurance system in China. At present,the HIV/AIDS testing laboratories includes three classes,the National AIDS Reference Laboratory,HIV/AIDS confirmatory laboratories and HIV/AIDS screening laboratories. All of them are accredited by the health authorities,and each class of laboratories take charge of their function strictly according to the "National Management of HIV/AIDS Detection (2006)". A complete quality assurance and quality control system for HIV/AIDS testing has been developed,which includes technical training,strict laboratory monitoring and approval,examination or proficiency testing on HIV/AIDS detection,and quality evaluation and supervision of HIV/AIDS diagnostic kits. Besides conduct the routine anti-HIV antibody test,more and more laboratories began to conduct other tests,such as CD4+ T lymphocyte cell counting,HIV viral load,HIV DNA PCR,genotyping,drug resistance,and HIV-1 recent infection test. The primary challenges faced by the HIV/AIDS testing laboratory network are in the areas of laboratory management and quality control. For example,the provincial PT program is inefficient,the internal quality control is conducted perfunctorily,personnel training can not met the needs of the workplace,which need to be improved.

HIV/AIDS in Asia:The Shape of Epidemics and Their Molecular Epidemiology

The Asia-Pacific region is a home to 60% of the population in the world and to approximately one quarter of people with HIV/AIDS. Close to a million of people has been infected and a half million people died of AIDS annually in Asia,becoming the second largest epicenter of global AIDS epidemic. Molecular epidemiology has been useful tool to track a course of HIV spread. In-depth knowledge from the studies on molecular epidemiology elucidates the dynamics of HIV spread and the interrelationship of epidemics in the different regions in Asia.

“Unconventional”Neutralizing Activity of Antibodies Against HIV

Neutralizing antibodies are recognized to be one of the essential elements of the adaptive immune response that must be induced by an effective vaccine against HIV. However, only a limited number of antibodies have been identified to neutralize a broad range of primary isolates of HIV-1 and attempts to induce such antibodies by inununization were unsuccessful. The difficulties to generate such antibodies are mainly due to intrinsic properties of HIV-1 envelope spikes, such as high sequence diversity, heavy glycosylation, and inducible and transient nature of certain epitopes. In vitro neutralizing antibodies are identified using ＂conventional＂ neutralization assay which uses phytohemagglutinin （PHA）-stimulated human PBMCs as target cells. Thus, in essence the assay evaluates HIV-1 replication in CD4^＋T cells. Recently, several laboratories including us demonstrated that some monoclonal antibodies and HIV-1-specific polyclonal IgG purified from patient sera, although they do not have neutralizing activity when tested by the ＂conventional＂ neutralization assay, do exhibit potent and broad neutralizing activity in ＂unconventional＂ ways. The neutralizing activity of these antibodies and IgG fractions is acquired through post-translational modifications, through opsonization of virus particles into macrophages and inunature dendritic cells （iDCs）, or through expression of antibodies on the surface of HIV-1-susceptible cells. This review will focus on recent findings of this area and point out their potential applications in the development of preventive strategies against HIV.

HIV and HCV:from Co-infection to Epidemiology,Transmission,Pathogenesis,and Treatment

Human immunodeficiency virus (HIV) is the infectious agent causing acquired immu-nodeficiency syndrome (AIDS),a deadliest scourge of human society. Hepatitis C virus (HCV) is a major causative agent of chronic liver disease and infects an estimated 170 million people worldwide,resulting in a serious public health burden. Due to shared routes of transmission,co-infection with HIV and HCV has become common among individuals who had high risks of blood exposures. Among hemophiliacs the co-infection rate accounts for 85%; while among injection drug users (IDU) the rate can be as high as 90%. HIV can accelerate the progression of HCV-related liver disease,particularly when immunodeficiency has developed. Although the effect of HCV on HIV infection is controversial,most studies showed an increase in mortality due to liver disease. HCV may act as a direct cofactor to fasten the progression of AIDS and decrease the tolerance of highly active antiretroviral therapy (HARRT). Conversely,HAART-related hepatotoxicity may enhance the progression of liver fibrosis. Due to above complications,co-infection with HCV and HIV-1 has imposed a critical challenge in the management of these patients. In this review,we focus on the epidemiology and transmission of HIV and HCV,the impact of the two viruses on each other,and their treatment.

Novel Antiviral Agents Targeting HIV Entry and Transmission

Studies of the mechanism of HIV entry and transmission have identified multiple new targets for drug development. A range of inhibitors have demonstrated potent antiretroviral activity by interfering with CD4-gp120 interaction,coreceptor binding or viral-cell fusion in preclinical and clinical studies. One of these agents,fusion inhibitor enfuvirtide,is already in clinical use. Here we review the progress in the development of specific entry inhibitors as novel therapeutics. The potential of entry inhibitors as topical microbicides to block HIV transmission is also discussed.

Frequency and Absolute Number of FoxP3^+ Regulatory T Cells Correlate with Disease Progression of Chronic HIV-1 Infection

CD4^＋CD25^＋ Regulatory T cells （Treg） have been found to down-regulate immune activation in HIV-1 infection. However, whether the depletion of Treg benefits to the disease status of HIV infection remains undefined. To address this issue, we enumerated the Treg absolute counts and frequency in 75 antiviral-naive HIV-1-infected individuals in this study. It was found that HIV-infected patients displayed a significant decline in Treg absolute counts but a significant increase in Treg frequency. In addition, with disease progression indicated by CD4 T-cell absolute counts, circulating Treg frequency gradually increased; while Treg absolute counts were gradually decreased, suggesting that the alteration of Treg number closely correlated with disease progression in HIV infection Functional analysis further showed that Treg efficiently inhibit both CD4 and CD8 T cell proliferation in vitro. Thus, our findings indicates that Treg actively participate in pathogenesis of chronic HIV infection, influencing the disease progression.

Current Status of Targets and Assays for Anti-HIV Drug Screening

HIV/AIDS is one of the most serious public health challenges globally. Despite the great efforts that are being devoted to prevent,treat and to better understand the disease,it is one of the main causes of morbidity and mortality worldwide. Currently,there are 30 drugs or combinations of drugs approved by FDA. Because of the side-effects,price and drug resistance,it is essential to discover new targets,to develop new technology and to find new anti-HIV drugs. This review summarizes the major targets and assays currently used in anti-HIV drug screening.

Strategy for AIDS Prevention and Treatment

HIV/AIDS has been circulating in China for over 25 year. While making achievements on HIV/AIDS prevention, there still are great challenge and difficulties epidemic controlling and vaccine research .

Challenges and Opportunities:the Expanded Government-led HIV/AIDS Programs in China

HIV/AIDS has posed an increasingly serious issue in China. In recent years,Chinese government has taken further intensified efforts to combat HIV/AIDS with high-level political commitment,supportive policy development,increased financial allocation,large-scale of government-led initiatives,expanded international cooperation and great involvement of non-governmental organizations. Meanwhile gaps and challenges coexist impacting the implementation and the results of national HIV/AIDS programs. Thus,further government efforts are needed to improve and tailor the actions to meet the requirement of HIV/AIDS control in China.

AIDS Research and Its Role in China's AIDS Prevention and Control Policies

By the end of 2005,the estimated number of HIV infected people in China was 650,000. The seriousness of the epidemic calls for effective control measures to tackle the problems in order to avoid the tragedy in Africa from happening in China. "Prevention First" is the cornerstone of the country's health policy. On 2003 World AIDS Day,Premier Jiabao Wen announced a new national AIDS control policy,"Four Frees and One Care". This policy clearly shows that the Chinese government has once again taken full responsibility to solve public health problems and has profound impact far beyond the AIDS field. In early 2006,the central government put scientific and technology innovation as a national priority and set the target to build an innovative China by year 2020. Since then,the government has been increasing investment in science and technology with major emphasis on both infectious diseases control and new drug research and development. For the first time,development of 100 new drugs and control of major infectious diseases (AIDS,HBV,TB and other emerging infectious diseases) have been selected as national key scientific projects. China's best minds in related fields will be pooled to work together in order to remove the technical barriers blocking efficient control of the major infectious disease in China. Knowledge on molecular epidemiology,immunology,pathogenesis,HAART,as well as HIVDR strains will certainly provide urgently needed scientific information for China's AIDS control program. Only evidence-based strategy from good research will provide long-term effective control of AIDS.

HIV Vaccine-Challenges and Opportunities

The need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of an efficacious HIV/AIDS vaccine proves an enormous scientific challenge. This article reviews the neutralizing antibody problem,elusive immune protection,im-munogen design,pre-existing anti-vector immunity and design of phase 3 vaccine trials and the challenges and opportunities in development of HIV/AIDS vaccine are discussed.

A Few Specialized Issues That Should Be Focused on Anti-HIV Drug Evaluation In Vitro

Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the development of resistance to antiretroviral drugs, and more new anti-HIV drugs with lower toxicity and higher activity were needed. Based on the experience and lessons learned from the treatment in the developed countries, US FDA suggested that more pharmacodynamical researches should be considered ahead of the clinical trials. To facilitate the anti-HIV drug research and development, we reviewed a few specialized issues that should be focused on drug evaluations in vitro, including: 1) Mechanism of action studies, demonstrating the candidate drug's efficacy to specifically inhibit viral replication or a virus-specific function and confirm the drug target. 2) Drug resistance studies, selecting the drug-resistant variants in vitro and determining the activities inhibiting HIV isolates resistant to approved antiretroviral drugs of the same class. 3) Antiviral activity in vitro in the presence of serum proteins, ascertaining whether an investigational product is significantly bound by serum proteins. 4) Combination activity analysis, evaluating in vitro antiviral activity of an investigational product in two-drug combinations with other drugs approved.

Are BRICS Countries Winning the War on HIV/AIDS？ Magnitude and Risk Factors

The aim of this study was to analyse the responses to HIV/AIDS in BRICS （Brazil, Russia, India, China and South Africa） countries to determine if they are winning the war on this pandemic. The authors used a comparative case study approach and multiple data sources on HIV prevalence, incidence, mortality, and risk factors of HIV. BRICS has 42% of the world＇s population, a total of 11.1 million people living with HIV （PLHIV） and an average HIV prevalence of 2.8%. Overall, there were 11.1 million PLHIV, 739,909 new infections, and 592,786 deaths in BRICS countries in 2012. The magnitude of HIV in BRICS countries was Brazil （.5%）, Russia （1.1%）, India （.3%）, China （.1%）, and South Africa （12.2%）. New infections declined by 30% or more and overall prevalence and deaths also declined in Brazil, India, China, and South Africa. The epidemic has stabilized in Brazil at .6%. Russia has one of the world＇s fastest-growing H1V epidemics, India has the largest burden of HIV in Asia and South Africa has the largest number of PLHIV. During a 10 year period, Russia had a 47% increase in new HIV infections. This suggests that Russia may be losing the battle against HIV at this stage. On the other hand, India and South Africa seem to have turned the corner with declines in HIV infections of 43% and 38% respectively.

Safety Concerns about the Application of Moxa

Objective： To discuss the safety issues of moxibustion therapy in view of moxibustion materials. Methods： The analyses and assessment were performed based on the survey carried out on the use of moxa, modem and ancient records, modem studies, and clinical applications. Results： Moxa has been used as both a medicine and a food for a long history in China. Regarding moxibustion specifically, moxa has been proven to be the optimum choice for moxibustion therapy, through practices and experiments by doctors from different generations. No records have shown any sideor adverse-effects of moxa applied in moxibustion therapy. Conclusion： Moxa has been used in multiple ways for several thousands of years by Chinese people. As the main material for moxibustion therapy, its safety has been proven by documents and clinical practices.

Clinical Study on Moxibustion at Shenque(CV 8)for Chronic Urticaria

Objective:To observe the safety and efficacy of moxibustion at Shenque(CV 8)for chronic urticaria.Methods:A total of 80 cases who met the inclusion criteria were randomly allocated into a treatment group and a control group,40 in each.Cases in the treatment group were treated with thunder-fire moxibustion at Shenque(CV 8),whereas cases in the control group were treated with Mizolastine.Changes in clinical symptoms such as itching and skin lesion were observed before and after treatment and the therapeutic efficacies were assessed.Results:After treatment,the total scores of clinical symptoms in both groups were markedly reduced(P<0.05),and the reduction was more significant in the treatment group than that in the control group(P<0.05).The total effective rate in the treatment group was 77.5%,versus 65.0%in the control group,showing no significant difference(P>0.05).The Ridit analysis showed a between-group significant difference in therapeutic efficacy grades(P<0.05).There were no reports of adverse reactions in the treatment group and 2 cases experienced mild somnolence in the control group.Conclusion:With an exact effect for chronic urticaria,moxibustion at Shenque(CV 8)obtained better results in overall efficacy and improving symptoms than oral administration of Mizolastine.

Review on Clinical and Mechanism Studies of Moxibustion Therapy for Chronic Gastritis

By computer research, the literature of clinical and experimental studies on moxibustion therapy for chronic gastritis in the recent fifteen years was collected, sorted and analyzed, in order to understand the general situation about the clinical and experimental studies on moxibustion therapy for chronic gastritis, summarize the regularity of moxibustion therapy for chronic gastritis, so as to guide the treatment of chronic gastritis.

Study on the Effect of Moxibustion in Treating Rhreumatoid Arthritis Rats and Its Mechanism

Objective： To investigate the therapeutic efficacy of moxibustion in treating rheumatoid arthritis （RA） and its mechanism. Methods： A hundred male Wistar rats were randomized into 5 groups, 20 in each group. RA models were developed in all groups except for the normal group. When the models were successfully prepared, the rats in the normal group and the model group didn’t receive any treatment. Those in the moxibustion group received suspended moxibustion by moxa stick, those in the cigarette group received fumigation by cigarette; while those in the moxa oil group were treated by applying moxa essential oil to acupoints. After consecutive 15-day treatment, body weight, paw circumference, thymus and spleen indexes were compared among the five groups, and the expression of Fas/FasL protein in synovium of rat’s joint was detected by using immunohistochemical （IHC） method. Results： After treatment, the moxibustion group had body weight increased, joint swelling relieved, thymus index enhanced, spleen index dropped, and the expression of Fas/FasL protein raised. Regarding the above indexes, the moxibustion group and the cigarette group showed more significant improvements than the moxa oil group; the moxibustion group had more significant effect on the expression of Fas/FasL than the cigarette group. Conclusion： Moxibustion obviously improves the symptoms of RA rats, regulates the expression of Fas/FasL protein in synovium of rat’s joint, and induces apoptosis of synovial cells, which maybe one of the mechanisms of moxibustion in achieving the warming and unblocking effect.